DelveInsight’s “Chemotherapy Induced Peripheral Neuropathy Market Insight, Epidemiology And Market Forecast – 2034” report delivers an in-depth understanding of the CIPN, historical and forecasted epidemiology, as well as CIPN market trends across the United States, EU4 (Germany, Spain, Italy, and France), the UK, and Japan. The report highlights that CIPN remains a frequent, dose-dependent complication of anticancer drugs, including platinum compounds, taxanes, epothilones, vinca alkaloids, and newer agents like bortezomib, significantly impacting patients’ quality of life and often necessitating dose reduction or treatment discontinuation.
The chemotherapy-induced peripheral neuropathy market size is expected to witness a substantial positive shift in 7MM from 1.5 billion in 2023. Among the 7MM, the US accounted for the largest CIPN market size with more than USD 900 million. Furthermore, among the EU4 and the UK, Germany accounted for the highest market size in 2023.
Download the Chemotherapy-Induced Peripheral Neuropathy Market Forecast Report to understand which factors are driving the CIPN therapeutic market @ Chemotherapy-Induced Peripheral Neuropathy Market Trends.
According to the recent CIPN epidemiological data cited in the report, the total chemotherapy-induced peripheral neuropathy incidence in the 7MM was 1.6 million in 2023. As per DelveInsight’s estimates, the overall incidence of moderate CIPN was maximum, followed by mild and then severe. Moreover, the CIPN incident cases based on chemotherapeutic agents were highest for platinum drugs, with around 47% in the US, followed by taxanes and vinca alkaloids.
Regional analysis reveals that the US captured the largest chemotherapy-induced peripheral neuropathy incident cases among 7MM, with more than 40% of total cases. Among EU4 and the UK, Germany accounted for the highest CIPN incident cases in 2023.
Discover evolving trends in the CIPN patient pool forecasts @ Chemotherapy-Induced Peripheral Neuropathy Epidemiology Analysis.
The current treatment landscape remains limited, with duloxetine standing as the only medication endorsed by the American Society of Clinical Oncology specifically for CIPN management. Among available therapies, the highest market revenue was generated by opioid analgesics, with approximately 50% of total revenue generated in 2023.
Other therapeutic approaches include serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, opioids, and topical analgesics, though these are primarily utilized for symptomatic relief rather than addressing underlying pathophysiology. Importantly, there are currently no FDA-approved medications for CIPN prevention, highlighting a critical unmet need in oncology supportive care.
The CIPN pipeline is witnessing remarkable innovation with several promising candidates in late-stage development. HALNEURON by WEX Pharmaceuticals has demonstrated encouraging results in clinical trials for treating chemotherapy-induced neuropathic pain. This selective voltage-gated sodium channel blocker represents a potential breakthrough in non-opioid analgesics for chemotherapy-induced peripheral neuropathy management.
Another notable candidate is E-52862 by Esteve, a selective sigma-1 receptor antagonist, which has shown superior relief of chronic postsurgical pain compared to placebo in phase II studies. Despite launching later than Tetrodotoxin, analysts predict E-52862 will create a comparatively greater market impact due to its target-specific CIPN mechanism.
Additionally, ATX01, developed by AlgoTx, a first-in-class topical treatment formulated as a hydrogel containing amitriptyline, is designed to be applied directly to the skin over affected areas. By targeting the epidermis and dermis-where damaged nerve fibers responsible for neuropathic pain are located, ATX01 delivers the active drug locally, minimizing systemic absorption and thereby reducing the risk of widespread side effects commonly seen with oral or intravenous pain medications. The drug is currently in Phase II, and the FDA granted Fast Track Designation to ATX01 for the treatment of chemotherapy-induced peripheral neuropathy CIPN in June 2022.
In January 2025, the FDA announced the availability of a draft guidance titled “Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology.” This guidance provides recommendations for the clinical development of drugs and biological products targeting CIPN. This reflects the agency’s recognition of the unmet need for effective therapies in this area.
Furthermore, in July 2024, the FDA cleared Artelo Biosciences’ IND application for ART26.12, a selective FABP5 inhibitor. This clearance enables the initiation of a Phase I clinical trial for ART26.12 in patients with CIPN. ART26.12 is notable for being the first selective FABP5 inhibitor to enter clinical trials, representing a novel, non-opioid, peripherally acting approach for managing painful neuropathies. Recent developments like these indicate a growing focus on developing targeted therapies for CIPN.
Discover evolving trends in the CIPN treatment landscape @ Chemotherapy-Induced Peripheral Neuropathy Recent Developments.
Looking ahead, the chemotherapy-induced peripheral neuropathy market is expected to witness substantial growth, driven by the increased focus on targeted therapies, the anticipated launch of novel therapies, and the rising cancer burden across geographies. However, challenges persist, including the need for standardized assessment tools, personalized treatment approaches based on chemotherapy agents and patient risk factors, and cost-effective interventions that meaningfully improve patient outcomes and quality of life.
Table of Contents
1. Key Insights
2. Report Introduction
3. Chemotherapy-induced Peripheral Neuropathy Market Overview at a Glance
4. Executive Summary of Chemotherapy-induced peripheral neuropathy (CIPN)
5. Key Events
6. Disease Background and Overview
7. CIPN Treatment and Management of CIPN
8. Methodology
9. CIPN Epidemiology and Patient Population
10. CIPN Patient Journey
11. CIPN Emerging Therapies
12. Chemotherapy-induced Peripheral Neuropathy (CIPN): Seven Major Market Analysis
13. KOL Views
14. SWOT Analysis
15. CIPN Unmet needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
Related Reports:
Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Insight
Chemotherapy Induced Peripheral Neuropathy Pipeline Insight provides comprehensive insights about the CIPN pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the CIPN companies, including Grünenthal GmbH, AlgoTherapeutix, and Wex Pharmaceuticals Inc, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Arpit AnandEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
